Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Esophageal Cancer | Research

Predictive and prognostic markers from endoscopic ultrasound with biopsies during definitive chemoradiation therapy in esophageal squamous cell carcinoma

Authors: Qingwu Du, Xiaoyue Wu, Kunning Zhang, Fuliang Cao, Gang Zhao, Xiaoying Wei, Zhoubo Guo, Yang Li, Jie Dong, Tian Zhang, Wencheng Zhang, Ping Wang, Xi Chen, Qingsong Pang

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Introduction

Endoscopic ultrasound (EUS) may play a role in evaluating treatment response after definitive chemoradiation therapy (dCRT) for esophageal squamous cell carcinoma (ESCC). This study explored the prognostic markers of EUS with biopsies and developed two nomograms for survival prediction.

Methods

A total of 821 patients newly diagnosed with ESCC between January 2015 and December 2019 were reviewed. We investigated the prognostic value of the changes in tumor imaging characteristics and histopathological markers by an interim response evaluation, including presence of stenosis, ulceration, tumor length, tumor thickness, lumen involvement, and tumor remission. Independent prognostic factors of progression-free survival (PFS) and overall survival (OS) were determined using Cox regression analysis and further selected to build two nomogram models for survival prediction. The receiver operating characteristic (ROC) curve, calibration curve, and decision curve analysis (DCA) were used to respectively assess its discriminatory capacity, predictive accuracy, and clinical usefulness.

Results

A total of 155 patients were enrolled in this study and divided into the training (109 cases) and testing (46 cases) cohorts. Tumor length, residual tumor thickness, reduction in tumor thickness, lumen involvement, and excellent remission (ER) of spatial luminal involvement in ESCC (ER/SLI) differed significantly between responders and non-responders. For patients undergoing dCRT, tumor stage (P = 0.001, 0.002), tumor length (P = 0.013, 0.008), > 0.36 reduction in tumor thickness (P = 0.004, 0.004) and ER/SLI (P = 0.041, 0.031) were independent prognostic markers for both PFS and OS. Time-dependent ROC curves, calibration curves, and DCA indicated that the predicted survival rates of our two established nomogram models were highly accurate.

Conclusion

Our nomogram showed high accuracy in predicting PFS and OS for ESCC after dCRT. External validation and complementation of other biomarkers are needed in further studies.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kamarajah SK, Phillips AW, Hanna GB, et al. Definitive Chemoradiotherapy compared to Neoadjuvant Chemoradiotherapy with Esophagectomy for Locoregional Esophageal Cancer: National Population-based Cohort Study. Ann Surg. 2022;275:526–33.CrossRefPubMed Kamarajah SK, Phillips AW, Hanna GB, et al. Definitive Chemoradiotherapy compared to Neoadjuvant Chemoradiotherapy with Esophagectomy for Locoregional Esophageal Cancer: National Population-based Cohort Study. Ann Surg. 2022;275:526–33.CrossRefPubMed
2.
go back to reference Yang S, Lin S, Li N, et al. Burden, trends, and risk factors of esophageal cancer in China from 1990 to 2017: an up-to-date overview and comparison with those in Japan and South Korea. J Hematol Oncol. 2020;13:146.CrossRefPubMedPubMedCentral Yang S, Lin S, Li N, et al. Burden, trends, and risk factors of esophageal cancer in China from 1990 to 2017: an up-to-date overview and comparison with those in Japan and South Korea. J Hematol Oncol. 2020;13:146.CrossRefPubMedPubMedCentral
3.
go back to reference Teoh AY, Chiu PW, Yeung WK, et al. Long-term survival outcomes after definitive chemoradiation versus surgery in patients with resectable squamous carcinoma of the esophagus: results from a randomized controlled trial. Ann Oncol. 2013;24:165–71.CrossRefPubMed Teoh AY, Chiu PW, Yeung WK, et al. Long-term survival outcomes after definitive chemoradiation versus surgery in patients with resectable squamous carcinoma of the esophagus: results from a randomized controlled trial. Ann Oncol. 2013;24:165–71.CrossRefPubMed
4.
go back to reference Shah MA, Kennedy EB, Catenacci DV, et al. Treatment of locally Advanced Esophageal Carcinoma: ASCO Guideline. J Clin Oncol. 2020;38:2677–94.CrossRefPubMed Shah MA, Kennedy EB, Catenacci DV, et al. Treatment of locally Advanced Esophageal Carcinoma: ASCO Guideline. J Clin Oncol. 2020;38:2677–94.CrossRefPubMed
5.
go back to reference Markar S, Gronnier C, Duhamel A, et al. Salvage surgery after Chemoradiotherapy in the management of Esophageal Cancer: is it a viable therapeutic option? J Clin Oncol. 2015;33:3866–73.CrossRefPubMed Markar S, Gronnier C, Duhamel A, et al. Salvage surgery after Chemoradiotherapy in the management of Esophageal Cancer: is it a viable therapeutic option? J Clin Oncol. 2015;33:3866–73.CrossRefPubMed
6.
go back to reference Welsh J, Settle SH, Amini A, et al. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer. 2012;118:2632–40.CrossRefPubMed Welsh J, Settle SH, Amini A, et al. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer. 2012;118:2632–40.CrossRefPubMed
7.
go back to reference Ren X, Wang L, Han C, et al. Retrospective analysis of safety profile of high-dose concurrent chemoradiotherapy for patients with oesophageal squamous cell carcinoma. Radiother Oncol. 2018;129:293–9.CrossRefPubMed Ren X, Wang L, Han C, et al. Retrospective analysis of safety profile of high-dose concurrent chemoradiotherapy for patients with oesophageal squamous cell carcinoma. Radiother Oncol. 2018;129:293–9.CrossRefPubMed
8.
go back to reference Chang CL, Tsai HC, Lin WC, et al. Dose escalation intensity-modulated radiotherapy-based concurrent chemoradiotherapy is effective for advanced-stage thoracic esophageal squamous cell carcinoma. Radiother Oncol. 2017;125:73–9.CrossRefPubMed Chang CL, Tsai HC, Lin WC, et al. Dose escalation intensity-modulated radiotherapy-based concurrent chemoradiotherapy is effective for advanced-stage thoracic esophageal squamous cell carcinoma. Radiother Oncol. 2017;125:73–9.CrossRefPubMed
9.
go back to reference Short MW, Burgers KG, Fry VT. Esophageal Cancer. Am Fam Physician. 2017;95:22–8.PubMed Short MW, Burgers KG, Fry VT. Esophageal Cancer. Am Fam Physician. 2017;95:22–8.PubMed
10.
go back to reference Noordman BJ, Spaander MCW, Valkema R, et al. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study. Lancet Oncol. 2018;19:965–74.CrossRefPubMed Noordman BJ, Spaander MCW, Valkema R, et al. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study. Lancet Oncol. 2018;19:965–74.CrossRefPubMed
11.
go back to reference van der Bogt RD, Noordman BJ, Krishnadath KK, et al. Endoscopic ultrasound measurements for detection of residual disease after neoadjuvant chemoradiotherapy for esophageal cancer. Endoscopy. 2019;51:326–32.CrossRefPubMed van der Bogt RD, Noordman BJ, Krishnadath KK, et al. Endoscopic ultrasound measurements for detection of residual disease after neoadjuvant chemoradiotherapy for esophageal cancer. Endoscopy. 2019;51:326–32.CrossRefPubMed
12.
go back to reference Qian D, Wang Y, Zhao G, et al. Tumor Remission and Tumor-Infiltrating lymphocytes during chemoradiation therapy: predictive and prognostic markers in locally advanced esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2019;105:319–28.CrossRefPubMed Qian D, Wang Y, Zhao G, et al. Tumor Remission and Tumor-Infiltrating lymphocytes during chemoradiation therapy: predictive and prognostic markers in locally advanced esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2019;105:319–28.CrossRefPubMed
13.
go back to reference Yeom JG, Kim JH, Kim JW et al. Prognostic Significance of Interim Response Evaluation during Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.Cancers (Basel)2021;13. Yeom JG, Kim JH, Kim JW et al. Prognostic Significance of Interim Response Evaluation during Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.Cancers (Basel)2021;13.
14.
go back to reference Yu JP, Lu WB, Wang JL, et al. Pathologic response during chemo-radiotherapy and variation of serum VEGF levels could predict effects of chemo-radiotherapy in patients with esophageal cancer. Asian Pac J Cancer Prev. 2015;16:1111–6.CrossRefPubMed Yu JP, Lu WB, Wang JL, et al. Pathologic response during chemo-radiotherapy and variation of serum VEGF levels could predict effects of chemo-radiotherapy in patients with esophageal cancer. Asian Pac J Cancer Prev. 2015;16:1111–6.CrossRefPubMed
15.
go back to reference Brun E, Zatterstrom U, Kjellen E, et al. Prognostic value of histopathological response to radiotherapy and microvessel density in oral squamous cell carcinomas. Acta Oncol. 2001;40:491–6.CrossRefPubMed Brun E, Zatterstrom U, Kjellen E, et al. Prognostic value of histopathological response to radiotherapy and microvessel density in oral squamous cell carcinomas. Acta Oncol. 2001;40:491–6.CrossRefPubMed
16.
go back to reference Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefPubMed Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefPubMed
17.
go back to reference Qiu B, Wang D, Yang H, et al. Combined modalities of magnetic resonance imaging, endoscopy and computed tomography in the evaluation of tumor responses to definitive chemoradiotherapy in esophageal squamous cell carcinoma. Radiother Oncol. 2016;121:239–45.CrossRefPubMed Qiu B, Wang D, Yang H, et al. Combined modalities of magnetic resonance imaging, endoscopy and computed tomography in the evaluation of tumor responses to definitive chemoradiotherapy in esophageal squamous cell carcinoma. Radiother Oncol. 2016;121:239–45.CrossRefPubMed
19.
go back to reference Schob S, Meyer HJ, Dieckow J et al. Histogram Analysis of Diffusion Weighted Imaging at 3T is Useful for Prediction of Lymphatic Metastatic Spread, Proliferative Activity, and Cellularity in Thyroid Cancer.Int J Mol Sci2017;18. Schob S, Meyer HJ, Dieckow J et al. Histogram Analysis of Diffusion Weighted Imaging at 3T is Useful for Prediction of Lymphatic Metastatic Spread, Proliferative Activity, and Cellularity in Thyroid Cancer.Int J Mol Sci2017;18.
20.
go back to reference Borggreve AS, Goense L, van Rossum PSN, et al. Preoperative prediction of pathologic response to Neoadjuvant Chemoradiotherapy in patients with Esophageal Cancer using (18)F-FDG PET/CT and DW-MRI: a prospective Multicenter Study. Int J Radiat Oncol Biol Phys. 2020;106:998–1009.CrossRefPubMedPubMedCentral Borggreve AS, Goense L, van Rossum PSN, et al. Preoperative prediction of pathologic response to Neoadjuvant Chemoradiotherapy in patients with Esophageal Cancer using (18)F-FDG PET/CT and DW-MRI: a prospective Multicenter Study. Int J Radiat Oncol Biol Phys. 2020;106:998–1009.CrossRefPubMedPubMedCentral
21.
go back to reference Sakurada A, Takahara T, Kwee TC, et al. Diagnostic performance of diffusion-weighted magnetic resonance imaging in esophageal cancer. Eur Radiol. 2009;19:1461–9.CrossRefPubMed Sakurada A, Takahara T, Kwee TC, et al. Diagnostic performance of diffusion-weighted magnetic resonance imaging in esophageal cancer. Eur Radiol. 2009;19:1461–9.CrossRefPubMed
22.
go back to reference Ribeiro A, Franceschi D, Parra J, et al. Endoscopic ultrasound restaging after neoadjuvant chemotherapy in esophageal cancer. Am J Gastroenterol. 2006;101:1216–21.CrossRefPubMed Ribeiro A, Franceschi D, Parra J, et al. Endoscopic ultrasound restaging after neoadjuvant chemotherapy in esophageal cancer. Am J Gastroenterol. 2006;101:1216–21.CrossRefPubMed
23.
go back to reference Mesenas S, Vu C, McStay M, et al. A large series, resection controlled study to assess the value of radial EUS in restaging gastroesophageal cancer following neoadjuvant chemotherapy. Dis Esophagus. 2008;21:37–42.CrossRefPubMed Mesenas S, Vu C, McStay M, et al. A large series, resection controlled study to assess the value of radial EUS in restaging gastroesophageal cancer following neoadjuvant chemotherapy. Dis Esophagus. 2008;21:37–42.CrossRefPubMed
24.
go back to reference Chak A, Canto MI, Cooper GS, et al. Endosonographic assessment of multimodality therapy predicts survival of esophageal carcinoma patients. Cancer. 2000;88:1788–95.CrossRefPubMed Chak A, Canto MI, Cooper GS, et al. Endosonographic assessment of multimodality therapy predicts survival of esophageal carcinoma patients. Cancer. 2000;88:1788–95.CrossRefPubMed
25.
go back to reference Wu Y, Li J. Change in maximal esophageal Wall Thickness provides prediction of survival and recurrence in patients with esophageal squamous cell Carcinoma after Neoadjuvant Chemoradiotherapy and surgery. Cancer Manag Res. 2021;13:2433–45.CrossRefPubMedPubMedCentral Wu Y, Li J. Change in maximal esophageal Wall Thickness provides prediction of survival and recurrence in patients with esophageal squamous cell Carcinoma after Neoadjuvant Chemoradiotherapy and surgery. Cancer Manag Res. 2021;13:2433–45.CrossRefPubMedPubMedCentral
26.
go back to reference Shim CN, Song MK, Lee HS, et al. Prediction of survival by tumor area on endosonography after definitive chemoradiotherapy for locally advanced squamous cell carcinoma of the esophagus. Digestion. 2014;90:98–107.CrossRefPubMed Shim CN, Song MK, Lee HS, et al. Prediction of survival by tumor area on endosonography after definitive chemoradiotherapy for locally advanced squamous cell carcinoma of the esophagus. Digestion. 2014;90:98–107.CrossRefPubMed
27.
go back to reference Suzuki A, Xiao L, Hayashi Y, et al. Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy. Oncology. 2012;82:108–13.CrossRefPubMed Suzuki A, Xiao L, Hayashi Y, et al. Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy. Oncology. 2012;82:108–13.CrossRefPubMed
28.
go back to reference Yip C, Landau D, Kozarski R, et al. Primary esophageal cancer: heterogeneity as potential prognostic biomarker in patients treated with definitive chemotherapy and radiation therapy. Radiology. 2014;270:141–8.CrossRefPubMed Yip C, Landau D, Kozarski R, et al. Primary esophageal cancer: heterogeneity as potential prognostic biomarker in patients treated with definitive chemotherapy and radiation therapy. Radiology. 2014;270:141–8.CrossRefPubMed
29.
go back to reference Larue R, Klaassen R, Jochems A, et al. Pre-treatment CT radiomics to predict 3-year overall survival following chemoradiotherapy of esophageal cancer. Acta Oncol. 2018;57:1475–81.CrossRefPubMed Larue R, Klaassen R, Jochems A, et al. Pre-treatment CT radiomics to predict 3-year overall survival following chemoradiotherapy of esophageal cancer. Acta Oncol. 2018;57:1475–81.CrossRefPubMed
30.
go back to reference Duan J, Xie Y, Qu L, et al. A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy. J Immunother Cancer. 2018;6:100.CrossRefPubMedPubMedCentral Duan J, Xie Y, Qu L, et al. A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy. J Immunother Cancer. 2018;6:100.CrossRefPubMedPubMedCentral
31.
go back to reference Noordman BJ, van Lanschot JJB, group Ss. Oesophageal preservation in locally advanced oesophageal cancer - authors’ reply. Lancet Oncol. 2018;19:e431.CrossRefPubMed Noordman BJ, van Lanschot JJB, group Ss. Oesophageal preservation in locally advanced oesophageal cancer - authors’ reply. Lancet Oncol. 2018;19:e431.CrossRefPubMed
Metadata
Title
Predictive and prognostic markers from endoscopic ultrasound with biopsies during definitive chemoradiation therapy in esophageal squamous cell carcinoma
Authors
Qingwu Du
Xiaoyue Wu
Kunning Zhang
Fuliang Cao
Gang Zhao
Xiaoying Wei
Zhoubo Guo
Yang Li
Jie Dong
Tian Zhang
Wencheng Zhang
Ping Wang
Xi Chen
Qingsong Pang
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-10803-8

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine